Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.
Iridex Corporation develops, manufactures, and markets laser-based medical systems, delivery devices, procedure probes, accessories, and consumable instrumentation for ophthalmology. Its products support treatment of glaucoma, diabetic macular edema, and other retinal diseases, with proprietary MicroPulse® technology used across parts of its portfolio.
Iridex news commonly covers quarterly and annual financial results, business updates, product-family activity for systems such as Cyclo G6®, retina laser platforms including PASCAL®, IQ 532®, IQ 577®, and OcuLight® TX, and clinical literature involving MicroPulse transscleral laser therapy. Company updates also address commercial partnerships, U.S. direct sales, international distributor activity, operational efficiency measures, and Nasdaq listing-status matters.
Iridex (Nasdaq: IRIX) will release its second quarter 2026 financial results and provide a business update after the market close on August 18, 2026. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET, with phone and webcast access available.
Iridex (Nasdaq: IRIX) expanded its partnership with ophthalmology-focused group purchasing organization EyeProGPO by adding Iridex’s EndoProbe® Handpieces to the EyeProGPO product offering. More than 4,300 EyeProGPO members now gain access to preferred pricing on these single-use vitreoretinal laser delivery devices.
The addition complements Iridex’s existing EyeProGPO portfolio, which already includes PASCAL®, IQ 532®, IQ 577®, OcuLight® TX, Cyclo G6® laser consoles and MicroPulse P3®, G-Probe®, and G-Probe Illuminate® devices. According to Iridex, the expanded agreement is intended to broaden member access to its retina laser systems and support ophthalmic providers with a wider range of EndoProbe models and gauges.
Iridex (Nasdaq: IRIX) will present at the Planet MicroCap Las Vegas 2026 Conference. Management is scheduled to present on Wednesday, June 17, 2026 at 4:00 pm PT.
A live and archived webcast will be available via the Event Calendar in the Investors section of the company website.
Iridex (Nasdaq: IRIX) reported Q1 2026 revenue of $11.8 million, down 1% year-over-year. Cyclo G6 product revenue rose 14% to $3.6 million, while retina revenue declined to $5.8 million. Gross margin was 40%, operating expenses fell 4% to $5.1 million, and net loss narrowed to $0.5 million ($0.03 per share).
Non-GAAP adjusted EBITDA was $0.3 million. Cash was $4.6 million, down $1.4 million, with usage concentrated in Q1. Iridex reaffirmed 2026 revenue guidance of $51–$53 million, expects 2026 adjusted operating expenses of $19–$19.5 million, and projects positive operating cash flow for fiscal 2026.
Iridex (Nasdaq: IRIX) will release first-quarter 2026 financial results and provide a business update after market close on May 19, 2026. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET with live and recorded webcast access via the company website.
Investors can join by phone using Conference ID 9329659 or listen on the Events page at www.iridex.com.
Iridex (Nasdaq: IRIX) announced a partnership with EyeProGPO on April 7, 2026 to provide preferred pricing and expanded access to Iridex retina lasers for more than 1,800 EyeProGPO members.
The agreement adds PASCAL®, IQ 532®, IQ 577®, and OcuLight® TX to EyeProGPO offerings and builds on existing Cyclo G6® and glaucoma probe contracts, aiming to streamline purchasing and broaden clinical access for ophthalmology practices, ASCs, and hospitals.
Iridex (Nasdaq: IRIX) reported Q4 and full-year 2025 results with revenue momentum and cost reductions. Q4 revenue was $14.7M (+16% YoY) and full-year revenue was $52.7M (+8% YoY). Operating expenses declined 22% for FY2025 and adjusted EBITDA turned positive at $1.1M.
The company forecasts 2026 revenue of $51M–$53M and expects positive operating cash flow, while noting Middle East disruptions affecting deliveries.
Iridex (Nasdaq: IRIX) will report fourth quarter and full year 2025 financial results on March 26, 2026 after market close and provide a business update.
Management will host a conference call on March 26, 2026 at 2:00 p.m. PT / 5:00 p.m. ET with live and recorded webcast access on the company website.
Iridex (Nasdaq: IRIX) announced plans to relocate its headquarters from Mountain View, CA to San Jose, CA, under a non-binding letter of intent dated Jan 26, 2026. The company expects to occupy a 31,000 square foot location and forecasted savings of $0.4 million in fiscal 2026 and $0.6 million annualized.
The Lease terms remain subject to change and may not be executed as currently described; the company said the move aims to lower operating expenses while maintaining reduced manufacturing operations and Bay Area talent.
Iridex (NASDAQ: IRIX) reported preliminary unaudited results for the quarter and year ended Jan 3, 2026. Q4 2025 revenue is expected to be $14.6M–$14.8M, up 15%–17% year‑over‑year. The company achieved positive cash flow in Q4 and sold 15,800 Cyclo G6 probes (vs. 13,300 prior year). Full‑year 2025 revenue is expected to be $52.5M–$52.7M (about 8% growth). Iridex expects to achieve positive adjusted EBITDA for 2025. Results remain preliminary and subject to final close and audit.